Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
navenibart · 3 trials · 2 indications
An adverse event was any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product that did not necessarily have a causal relationship with the treatment. A treatment-emergent adverse event was defined as any adverse event with an onset at the time of or following the start of treatment with study drug, or medical conditions present before the start of treatment that increased in severity or relationship at the time of or following the start of treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' section.
| Arm | Type | Description |
|---|---|---|
| Adult Dosing Regimen 1 | EXPERIMENTAL | Participants will receive 600 mg of navenibart every 3 months. |
| Adult Dosing Regimen 2 | EXPERIMENTAL | Participants will receive 300 mg of navenibart every 3 months. |
| Adult Dosing Regimen 3 | EXPERIMENTAL | Participants will receive 600 mg of navenibart every 6 months. |
| Adolescent Dosing Regimen 1 | EXPERIMENTAL | Participants will receive 300 mg of navenibart every 3 months. |
| Adult Navenibart Dosing Regimen 1 | EXPERIMENTAL | Participants will receive 600 mg of navenibart every 3 months. |
| Adult Navenibart Dosing Regimen 2 | EXPERIMENTAL | Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3. |
| Adult Navenibart Dosing Regimen 3 | EXPERIMENTAL | Participants will receive 600 mg of navenibart every 6 months. |
| Placebo (adult) | PLACEBO_COMPARATOR | Participants will receive placebo every 3 months. |
| Adolescent Navenibart Dosing Regimen 1 | EXPERIMENTAL | Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3. |
| Cohort 1 - Single Dose | EXPERIMENTAL | Participants received 1 dose (450 milligrams \[mg\]) of navenibart. |
| Cohort 2 - Multiple Dose | EXPERIMENTAL | Participants received 2 doses (600 mg, 300 mg) of navenibart administered 3 months apart. |
| Cohort 3 - Multiple Dose | EXPERIMENTAL | Participants received 2 doses (600 mg) of navenibart administered 1 month apart. |
| Name | Type | Description |
|---|---|---|
| navenibart | DRUG | Navenibart will be administered as a subcutaneous injection. |
| Placebo | DRUG | Placebo will be administered as a subcutaneous injection. |
Inclusion Criteria: 1\. Participants from STAR-0215-301 who met one of the following conditions: 1. Completed STAR-0215-301 through the Day 181 visit 2. Withdrew from STAR-0215-301 but met the following criteria: i. Received 2 doses of IP ii. completed ≥ 2 months of trial follow-up after the seco...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Intellia Therapeutics, Inc. | NTLA | 3 | PHASE3 | NTLA-2002, Normal Saline Administration |
| BioCryst Pharmaceuticals, Inc. | BCRX | 2 | PHASE3 | Berotralstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Donidalorsen |
| Pharvaris N.V. | PHVS | 1 | PHASE2 | deucrictibant |
| BioMarin Pharmaceutical Inc. | BMRN | 1 | PHASE1 | Dose 1 of BMN 331 |
| Astria Therapeutics, Inc. | ATXS | 1 | PHASE2 | STAR-0215 |